Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Endonovo Therapeutics, Inc. (OTC: ENDV).

Full DD Report for ENDV

You must become a subscriber to view this report.


Recent News from (OTC: ENDV)

Endonovo beefs up SofPulse distribution in U.S.
Endonovo ( OTCQB:ENDV ) inks an agreement with privately held Magniant, LLC for the sales, marketing and distribution of SofPulse, its non-invasive Electroceutical Therapy for post-operative pain relief and reduction of swelling, in the Veterans Administration, Department of Defense, India...
Source: SeekingAlpha
Date: August, 14 2018 09:42
Endonovo Therapeutics Signs Distribution Agreement For National Distribution of Sofpulse® Electroceutical(TM) System
LOS ANGELES, CA, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc.  (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution agreement with Magniant, LLC (“Magniant”) for th...
Source: GlobeNewswire
Date: August, 14 2018 09:25
Endonovo Therapeutics Announces Enrollment of First Patient in Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical(TM) Therapy
LOS ANGELES, CA, June 14, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced that the first patient has been enrolled in a clinical study at the University of ...
Source: GlobeNewswire
Date: June, 14 2018 08:30
Endonovo Therapeutics Signs Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical(TM) SofPulse®
LOS ANGELES, CA, May 09, 2018 (GLOBE NEWSWIRE) --   Endonovo Therapeutics, Inc.  (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution agreement with Plagens Medical Consultants for the distri...
Source: GlobeNewswire
Date: May, 09 2018 13:30
Endonovo Therapeutics Highlights Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients
Company to Conduct Larger Clinical Study to Evaluate Its Electroceutical™ Therapy in Chronic Kidney Disease LOS ANGELES, CA, May 01, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc.  (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non...
Source: GlobeNewswire
Date: May, 01 2018 07:35
Endonovo Therapeutics Inc. to Move Forward with a Clinical Research Study Conducted by the Regents of the University of New Mexico
Los Angeles, CA, April 18, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc.  (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced an agreement to commence a clinical research study entit...
Source: GlobeNewswire
Date: April, 18 2018 10:00
Endonovo Reports Positive Results in Critical Limb Ischemia Study Using Non-Invasive Medical Device
LOS ANGELES, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc.  (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced positive results from a study of critical limb ischemia...
Source: GlobeNewswire
Date: February, 12 2018 09:32
Endonovo Reports Pre-Clinical Data Demonstrating Immunotronics(TM) Reduced Infarct Size and Inhibited Fibrosis following Myocardial Infarction
LOS ANGELES, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced positive results from a study of post-myocardial infarction remode...
Source: GlobeNewswire
Date: February, 01 2018 09:32
Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema
Seeking Distribution Partners in Europe for CE-Marked Electroceutical™ Device for Promotion of Wound Healing, Reduction of Pain and Post-Operative Edema LOS ANGELES, CA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc.  (OTCQB: ENDV) ("Endonovo" or the "Company...
Source: GlobeNewswire
Date: January, 22 2018 07:00
Endonovo Therapeutics Provides Corporate Update and 2018 Outlook
- Announces Series C Preferred Stock Offering  - Updates Status of Clinical Pipeline in Central Nervous System Disorders  LOS ANGELES, CA, Jan. 16, 2018 (GLOBE NEWSWIRE) --  -  Endonovo Therapeutics, Inc.  (OTCQB: ENDV) ("Endonovo" or the "Company"), a clini...
Source: GlobeNewswire
Date: January, 16 2018 09:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.02740.02390.02780.022,891,427
2018-12-070.0270.0250.0280.0252,030,026
2018-12-060.0310.0270.03150.02521,831,333
2018-12-050.0290.02690.03450.0253,166,596
2018-12-040.0290.02690.03450.0253,166,596

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-10645,3282,416,42726.7059Cover
2018-12-07325,1052,030,02616.0148Cover
2018-12-06244,3091,449,83316.8508Cover
2018-12-04405,1972,653,04615.2729Cover
2018-12-03583,1332,242,04726.0090Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ENDV.


About Endonovo Therapeutics, Inc. (OTC: ENDV)

Logo for Endonovo Therapeutics, Inc. (OTC: ENDV)

Endonovo Therapeutics OTCQB: ENDV is an innovative biotechnology company developing a bioelectronic approach to regenerative medicine. Endonovo s Immunotronics platform is a non invasive, non implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo s Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time Varying Electromagnetic Fields TVEMF for tissue engineering and cell therapies.

 

 

 

Current Management

  • Alan Collier / CEO, Interim CFO
  • Michael Mann / President
  • Don Calabria / COO
  • Steven Barnes / SVP, Inv. Rel.
  • Leonard Makowka / Chief Med. Officer
  • Alan Collier / Chairman

Current Share Structure

  • Market Cap: $12,149,446 - 03/15/2018
  • Authorized: 500,000,000 - 03/06/2018
  • Issue and Outstanding: 324,851,484 - 03/06/2018
  • Float: 622,092 - 05/18/2015

 


Recent Filings from (OTC: ENDV)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 06 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 03 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: December, 29 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 28 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 26 2017
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: November, 09 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 07 2017

 

 


Daily Technical Chart for (OTC: ENDV)

Daily Technical Chart for (OTC: ENDV)


Stay tuned for daily updates and more on (OTC: ENDV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ENDV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ENDV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ENDV and does not buy, sell, or trade any shares of ENDV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/